[Use of OKT-3 in treatment of rejection following kidney transplantation].
Application of OKT-3 as rescue therapy in steroid-resistant rejection was effective in 7 out of 9 patients early after cadaveric kidney transplantation. Under attention of instructions for use of OKT-3 the adverse first-dose reactions are rare. The problem of OKT-3 therapy is early use and its reuse.
Hansen
C
C
Urologische Klinik und Poliklinik, Humboldt-Universität Berlin.
Müller
P
P
Seibt
F
F
Oesterwitz
H
H
May
G
G
Strobelt
V
V
Kaden
J
J
Ditscherlein
G
G
Scholz
D
D
D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D003404:Creatinine / Q000097:blood; D005260:Female; D006084:Graft Rejection / Q000187:drug effects*; D006801:Humans; D007165:Immunosuppression Therapy; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D016030:Kidney Transplantation / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D016853:Muromonab-CD3; D011183:Postoperative Complications / Q000628:therapy*
D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D003404:Creatinine
Einsatz von OKT-3 bei der Rejektionsbehandlung nach Nierentransplantation.